Workspace
Mutation Evidence Board
Lung adenocarcinoma cohort / research-use review
Research workflow
Start here, then run analysis.
Use the sidebar for navigation. This panel only points to the next workflow step.
Run analysisStart a cohort analysis or continue the latest evidence review.
The workflow is linear: run analysis, review mutation relevance signals, export a research report, then share the client view.
Top signal
EGFR L858R
EGFR/ERBB signalling
Review queue
5 matches
2 reports ready
Cohorts
3
Demo datasets loaded
Samples
136
Across de-identified cohorts
Signals
15
Mutation relevance rows
Review
88
Top-signal average
Top mutation signals
Ranked for review
1. EGFR L858R
EGFR/ERBB signalling / EGFR inhibitor class
2. TP53 R175H
p53 tumour suppressor pathway / DNA damage response research marker
3. KRAS G12C
RAS/MAPK signalling / KRAS pathway inhibitor class
Hypotheses
Candidate shortlist
1. EGFR inhibitor class
Linked to EGFR L858R
2. KRAS / MEK pathway inhibition
Linked to KRAS G12D
3. KRAS / MEK pathway inhibition
Linked to KRAS G12C
Workflow actions
Cohort details
Lung adenocarcinoma demo cohort
Switch cohorts, check the input shape, and confirm what is ready for expert review.
Cohort
Lung adenocarcinoma demo cohort
Cancer type
Lung adenocarcinoma
Samples
48
Input
VCF / annotated mutation table
Candidate matches
5
Reports ready
2
Run health
Pipeline snapshot
Success
60%
Avg run
177s
Review
1
Ingest
HealthySchema and cohort checks
Annotate
HealthyPathway and mutation tags
Score
HealthyMutation relevance signals
Rank
DegradedCandidate hypothesis order
Report
HealthyEvidence brief export
Pathway view
Relevance distribution
Hover a pathway to inspect the linked mutation, candidate class, and evidence tags.
Recent runs
Activity queue
Recent activity
Amir exported evidence report rep-0023
18m ago
Amir completed cohort scoring run-2026-0142
24m ago
Lim uploaded cohort BRCA-2026-05.csv
2h ago
System queued retrospective benchmark bench-0037
3h ago
Keep the evidence trail visible before export.
Research-use only. ONCOQ.TECH produces evidence-ranked mutation signals and drug-repurposing hypotheses for investigation. Outputs are not clinical recommendations and must be reviewed by qualified experts before any validation or downstream use.